Q-omics provides the consensus-scored RHOU profile across patient tissues and cancer cell-line models. RHOU expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RHOU is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, RHOU RNA expression shows 20,380 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, COAD, and UVM as cancer lineages where RHOU shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RHOU — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RHOU survival associations across molecular data types. RHOU RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RHOU RNA expression–survival associations across cancer types. High RHOU expression shows unfavorable associations in UVM, ACC and LGG, but favorable associations in KIRC, MESO and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RHOU RNA expression.
This table summarizes RHOU tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for RHOU. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RHOU shows lower tumor expression in COAD, LUSC and BRCA and higher tumor expression in THCA, KIRC and LIHC. The COAD box plot shows higher RHOU RNA expression in normal versus tumor tissue (log2 FC = −1.500, t-test p < 0.001).
This table shows molecular features associated with RHOU in patient tissues and cancer cell lines. In patient samples, RHOU shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RHOU RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
